KR101383146B1 - Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease - Google Patents
Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease Download PDFInfo
- Publication number
- KR101383146B1 KR101383146B1 KR1020120052744A KR20120052744A KR101383146B1 KR 101383146 B1 KR101383146 B1 KR 101383146B1 KR 1020120052744 A KR1020120052744 A KR 1020120052744A KR 20120052744 A KR20120052744 A KR 20120052744A KR 101383146 B1 KR101383146 B1 KR 101383146B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- lettuce
- hangover
- liver disease
- chrysanthemum
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 206010019133 Hangover Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title abstract description 40
- 208000019423 liver disease Diseases 0.000 title abstract description 23
- 229940079593 drug Drugs 0.000 title description 16
- 239000003814 drug Substances 0.000 title description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 74
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 20
- 235000003228 Lactuca sativa Nutrition 0.000 claims abstract description 20
- 210000004207 dermis Anatomy 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 14
- 239000012676 herbal extract Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000000346 sugar Nutrition 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 241000208822 Lactuca Species 0.000 claims description 18
- 230000036541 health Effects 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 4
- 241000723353 Chrysanthemum Species 0.000 claims 4
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 17
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 8
- 241001672694 Citrus reticulata Species 0.000 abstract description 7
- 240000000249 Morus alba Species 0.000 abstract description 7
- 235000008708 Morus alba Nutrition 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 abstract description 3
- 230000036765 blood level Effects 0.000 abstract description 3
- 240000009226 Corylus americana Species 0.000 abstract description 2
- 235000001543 Corylus americana Nutrition 0.000 abstract description 2
- 235000007466 Corylus avellana Nutrition 0.000 abstract description 2
- 240000008415 Lactuca sativa Species 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 37
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 24
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 18
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 240000004371 Panax ginseng Species 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- -1 olive oil Chemical compound 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000208671 Campanulaceae Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 244000010000 Hovenia dulcis Species 0.000 description 2
- 235000008584 Hovenia dulcis Nutrition 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000354 acute hepatitis Toxicity 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- IECBDTGWSQNQID-JGVFFNPUSA-N (1r,5s)-4,6,6-trimethylbicyclo[3.1.1]hept-3-en-7-one Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2=O IECBDTGWSQNQID-JGVFFNPUSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- IECBDTGWSQNQID-UHFFFAOYSA-N Chrysanthenon Natural products CC1=CCC2C(C)(C)C1C2=O IECBDTGWSQNQID-UHFFFAOYSA-N 0.000 description 1
- IECBDTGWSQNQID-SFYZADRCSA-N Chrysanthenone Natural products CC1=CC[C@H]2C(C)(C)[C@@H]1C2=O IECBDTGWSQNQID-SFYZADRCSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 241000357622 Codonopsis javanica Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ACBOFPQSBWBAQR-UHFFFAOYSA-N Cosmosiin Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(Oc3c2)c4cccc(O)c4)C(O)C(O)C1O ACBOFPQSBWBAQR-UHFFFAOYSA-N 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- RKWHWFONKJEUEF-GQUPQBGVSA-O Cyanidin 3-O-glucoside Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-GQUPQBGVSA-O 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 239000000940 FEMA 2235 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229930195498 Hovenine Natural products 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- 241001521474 Liriope <hydrozoan> Species 0.000 description 1
- 241001532026 Liriope muscari Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000248557 Ophiopogon japonicus Species 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- MZOWOHKNFKJFFD-RRFJBIMHSA-N Sesquicarene Chemical compound C1CC(C)=C[C@H]2[C@@](CCC=C(C)C)(C)[C@H]21 MZOWOHKNFKJFFD-RRFJBIMHSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010056091 Varices oesophageal Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- QBYFCXBVWQQXFH-UHFFFAOYSA-N acaciin Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4OC6OCC(O)C(O)C6O)cc3O2 QBYFCXBVWQQXFH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 208000024170 esophageal varices Diseases 0.000 description 1
- 201000010120 esophageal varix Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000013761 grape skin extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- SUTSVCLKBLJSPQ-UHFFFAOYSA-N luteolin 7-glucoside Natural products OC1C(O)C(O)C(CO)OC1C1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SUTSVCLKBLJSPQ-UHFFFAOYSA-N 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000004069 plant analysis Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- XXHSUYNZCSBPBG-GZIDCZEMSA-N quercetin 3-beta-gentiotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC=3C(C4=C(O)C=C(O)C=C4OC=3C=3C=C(O)C(O)=CC=3)=O)O2)O)O1 XXHSUYNZCSBPBG-GZIDCZEMSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- XXHSUYNZCSBPBG-UHFFFAOYSA-N quercetin-3-gentotrioside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC2C(C(O)C(O)C(OC=3C(C4=C(O)C=C(O)C=C4OC=3C=3C=C(O)C(O)=CC=3)=O)O2)O)O1 XXHSUYNZCSBPBG-UHFFFAOYSA-N 0.000 description 1
- MZOWOHKNFKJFFD-UHFFFAOYSA-N rac-Sesquicaren Natural products C1CC(C)=CC2C(CCC=C(C)C)(C)C21 MZOWOHKNFKJFFD-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930013921 sesquicarene Natural products 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 갈화(칡꽃), 상심(오디), 오미자, 상엽(뽕잎), 지구자(헛개나무열매), 국호(국화), 진피(귤껍질), 맥문동 및 당삼(만삼)으로 구성된 복합생약 추출물을 유효성분으로 함유하는 간 질환 및 숙취의 예방 및 치료를 위한 조성물에 관한 것으로, 본 발명의 추출물은 in vitro 상에서 ADH 및 ALDH 효소 수준을 억제하고 in vivo 상에서는 Ethanol과 Acetaldehyde의 혈중 농도를 유의적으로 억제하는 숙취해소 및 간질환에 대한 치료 효과를 확인함으로써, 숙취해소 및 간질환의 예방 및 치료용 약학조성물에 이용될 수 있다.The present invention is a complex herbal extract consisting of galhwa (칡), lettuce (odie), Schisandra chinensis, upper leaf (mulberry), geoja (hazelnut), chrysanthemum (chrysanthemum), dermis (mandarin peel), Mcmundong and sugar ginseng (mansam) It relates to a composition for the prevention and treatment of liver disease and hangover containing as an active ingredient, the extract of the present invention in inhibits ADH and ALDH enzyme levels in vitro and in In vivo , by identifying the therapeutic effects of hangover and liver disease that significantly inhibits blood levels of ethanol and Acetaldehyde, it can be used in pharmaceutical compositions for hangover prevention and prevention and treatment of liver disease.
Description
본 발명은 갈화(칡꽃), 상심(오디), 오미자, 상엽(뽕잎), 지구자(헛개나무열매), 국호(국화), 진피(귤껍질), 맥문동 및 당삼(만삼)으로 구성된 복합생약 추출물을 유효성분으로 함유하는 숙취해소 및 간질환의 예방 및 치료용 조성물에 관한 것이다.The present invention is a complex herbal extract consisting of galhwa (칡), lettuce (odie), Schisandra chinensis, upper leaf (mulberry), geoja (hazelnut), chrysanthemum (chrysanthemum), dermis (mandarin peel), Mcmundong and sugar ginseng (mansam) It relates to a composition for relieving hangover and preventing and treating liver disease, which contains as an active ingredient.
[문헌 1] K. Ebihara et al., Agri. Biol. Chem., 52, 1311, 1988. Reference 1 K. Ebihara et al., Agri. Biol. Chem., 52, 1311, 1988.
[문헌 2] J. Caballeria et al., Life Sci., 41, 1021-1727, 1986.J. Caballeria et al., Life Sci., 41, 1021-1727, 1986.
[문헌 3] 김정한 등, 한국농화학회지, 38(6), 549-553, 1995.[Jeong-Han Kim, et al., Korean Journal of Agrochemicals, 38 (6), 549-553, 1995.
[문헌 4] 정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 704-706, 1998.[Ref. 4] Jung-Seop Shin and Min-Kyo Shin, Doha Hyang-Jeom (Medicinal Herb ) Ambassador , Younglimsa, pp 704-706, 1998.
[문헌 5] 정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 545-548, 1998.[Ref. 5] Jeong-Sup Jung and Shin Min-kyo Author, Dohae Hyang-je ( Drug Medicine), Korean Dictionary , Younglimsa, pp. 545-548, 1998.
[문헌 6] 정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 471-473, 1998.[Ref. 6] Jung-Seop Shin and Min-Kyo Shin, Do Hae Hyang Drug (Medicinal Herb ) Ambassador , Younglimsa, pp 471-473, 1998.
[문헌 7] 정보섭, 신민교, 도해향약대사전, 영림사, pp291-293, 1998.[Ref. 7] Jung-Seop Shin, Min-Kyo Shin, Dohae Hyangjeomsa Dictionary , Younglim History, pp291-293, 1998.
[문헌 8] 정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 1039-1040, 1998.[Ref. 8] Jung-Seop Shin and Min-Kyo Shin, Do Hae Hyang Drug (Medicinal Medicine) Metabolism , Younglimsa, pp 1039-1040, 1998.
[문헌 9] 정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 783-785, 1998.[Ref. 9] Jung-seop Jung and Shin Min-kyo Author, Dohae Hyang-je ( Drug ) Ambassador , Younglimsa, pp. 783-785, 1998.
[문헌 10] 정보섭외 향약대사전, 영림사, p177-178, 1998.[Ref. 10] Information Disclosure, Chinese Medicine History Dictionary , Younglim History, pp.177-178, 1998.
[문헌 11] 정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 1088-1089, 1998.[Document 11] Jung-Seop Shin and Min-Kyo Shin, Do Hae Hyang Drug (Medicinal Medicine) Ambassador , Younglimsa, pp. 1088-1089, 1998.
[문헌 12] Harborne J.B. Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. pp6-7, 1998.12. Harborne J.B. Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. pp 6-7, 1998.
[문헌 13] (재)한국보건공정서연구회 회장, 건강기능식품의 기능성시험가이드, (재)한국보건공정서연구회, pp 303-344, 2004.
[Reference 13] Chairman, Korea Institute of Health Procedures, Functional Test Guide for Health Functional Foods , Korea Institute of Health Procedures, pp 303-344, 2004.
우리나라 간질환 사망률은 인구 십만명 당 23.5명(남자 37.8명, 여자 9.0명)으로 매우 높으며, 40대 사망원인 1위(41.1명/10만명), 50대 사망원인 2위(72.4명/10만명), 30대 사망원인 3위(10명/10만명)를 차지하는 등 간질환은 한국 중년층 인구의 주요 사망원인이다. 특히 알콜성 간질환은 만성과다 음주자의 대부분에서 나타날 수 있는 질환이다.In Korea, liver disease mortality rate is very high, 23.5 per 100,000 population (37.8 males and 9.0 females), and the number of deaths in South Korea is the highest (41.1 / 100,000) and the second highest among the 50 deaths (72.4 / 100,000) , The third leading cause of death in the 30s (10 people / 100,000 people), is the leading cause of death in the Korean middle-aged population. Especially alcoholic liver disease is a disease that can occur in most of chronic overdoses.
간은 우리 몸에서 각종 대사 작용, 해독, 분해, 합성 및 분비를 담당하는 매우 중요한 장기로, 그 기능을 자세히 살펴보면 다음과 같다. 첫째, 간은 에너지 대사를 관리하는 기능이 있어 음식물에서 흡수된 모든 영양소들을 에너지를 생산할 수 있는 물질로 대사시켜 전신에 공급하거나 저장한다. 둘째, 간은 약 2,000여종의 효소, 알부민, 응고인자들의 혈청단백, 담즙산, 인지질, 콜레스테롤 등의 지방을 합성하고 저장하며 분배하는 기능이 있다. 셋째, 간은 각종 대사산물을 담관을 통해 십이지장으로 배설하는 기능이 있으며, 면역기능이 있어서 우리의 생명유지에 중요한 역할을 한다. 마지막으로, 간은 해독 및 분해 기능이 있어 약물, 독성물질, 술 등을 해독시킨다. 하지만 이러한 간의 해독기능은 간세포를 손상시키기 쉬워 약물성, 독성, 알코올성 간질환 등을 유발시킬 수 있다. The liver is a very important organ that is responsible for various metabolism, detoxification, decomposition, synthesis and secretion in our body. First, the liver has the function of managing the energy metabolism, and metabolizes all the nutrients absorbed from food into a substance capable of producing energy, and supplies or stores the whole body. Second, the liver has a function of synthesizing, storing and distributing fat of about 2,000 kinds of enzymes, albumin, serum proteins of bile coagulation factors, bile acid, phospholipid and cholesterol. Third, the liver has a function to excrete various metabolites through the bile duct into the duodenum, and it plays an important role in maintaining our life because of its immune function. Finally, the liver has detoxification and decomposition functions to detoxify drugs, toxic substances and alcohol. However, the hepatocyte detoxification function of this liver is liable to damage the drug, toxic and alcoholic liver disease can cause.
알코올성 간질환은 임상증상에 따라 알코올성 지방간, 알코올성 간염, 알코올성 간경변증으로 크게 나눌 수 있고 대개 하루 60-80g의 알코올을 10년 정도 마실 때 발생한다. 알코올성 지방간은 과다한 알코올 섭취로 인해 간세포 안에 콜레스테롤과 중성지방이 축적되어 발생하는 것으로 금주만 하게 되면 곧 회복할 수 있으나, 계속 음주하게 되면 간염으로 발전하게 된다. 알코올성 간염은 간세포의 괴사와 염증이 발생한 상태로, 피로감, 식욕부진, 체중감소, 황달, 발열, 우상복부통증 등의 다양한 증상을 보이며, 이를 앓는 환자 중 약 40%는 알코올성 간경변증으로 발전하게 된다. 알코올성 간경변증은 정상 간으로 회복이 불가능한 상태로, 전신 피로감, 식욕감퇴, 복수, 식도정맥류, 출혈, 간성뇌증, 혼수 등의 다양한 증상을 보이며, 간염 바이러스에 의한 간경변증보다 예후가 불량하여 구미(歐美)에서는 말기 간질환으로 인한 사망의 50%가 알코올에 의한 것으로 알려져 있다.Alcoholic liver disease can be divided into alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis according to the clinical symptoms and usually occur when drinking 60-80g of alcohol a day for 10 years. Alcoholic fatty liver is caused by accumulation of cholesterol and triglyceride in hepatocyte due to excessive alcohol consumption. It can be recovered soon after this week, but if it continues drinking, it develops into hepatitis. Alcoholic hepatitis has necrosis and inflammation of hepatocytes, and it has various symptoms such as fatigue, anorexia, weight loss, jaundice, fever, right upper abdominal pain, and about 40% of the patients develop alcoholic cirrhosis. Alcoholic cirrhosis is a condition that is impossible to recover from normal liver, and has various symptoms such as general fatigue, decreased appetite, ascites, esophageal varices, bleeding, hepatic encephalopathy, lethargy, and poor prognosis than cirrhosis caused by hepatitis virus. In Esau, 50% of deaths from end-stage liver disease are known to be caused by alcohol.
정상적인 에틸알콜 대사과정은 체내로 유입된 에틸알콜이 위장 또는 소장에서 흡수되어 혈과중에 들어가 간장으로 옮겨지게 된다. 간세포에는 알콜 탈수소효소(alcohol dehydrogenase, ADH)가 있어 알콜을 아세트알데히드로 산화시키고, 상기 아세트알데히드는 간세포에 있는 아세트알데히드 탈수소효소(acetaldehyde dehydrogenase)에 의해 초산으로 분해되어 전신의 근육이나 지방조직으로 옮겨져 최종적으로는 탄산가스와 물로 분해되는 것이다. 또한, 상기 아세트알데히드 탈수소효소에는 아세트알데히드가 저농도이더라도 산화를 개시하는 Ⅱ형과 아세트알데히드가 고농도로 되지 않으면 작용을 하지 않는 Ⅰ형이 있으나, 동양인은 일반적으로 Ⅱ형 아세트알데히드 효소가 결핍 또는 부족하기 때문에 아세트알데히드의 산화가 느리고, 따라서 산화되지 못한 아세트알데히드 및/또는 에틸알콜의 독작용에 의하여 정상적인 신진대사가 방해받아 다양한 숙취현상을 느끼게 되는 것이다. 이러한 음주 후의 숙취현상을 해소하기 위하여 생약제제 또는 인공제제를 단독 또는 혼합하여 제조한 드링크류가 다수 개발되었다.The normal course of ethyl alcohol metabolism is the absorption of ethyl alcohol into the body is absorbed in the stomach or small intestine into the blood and then transferred to the liver. Hepatocytes have alcohol dehydrogenase (ADH), which oxidizes alcohol to acetaldehyde. The acetaldehyde is decomposed into acetic acid by acetaldehyde dehydrogenase in hepatocytes and transferred to muscle or fat tissue of the whole body And finally decompose into carbon dioxide and water. In addition, the acetaldehyde dehydrogenase enzyme has type Ⅱ which initiates oxidation even when acetaldehyde is low in concentration, and type Ⅰ which does not work if acetaldehyde is not concentrated in high concentration. However, Asian people generally have deficiency or lack of Ⅱ type acetaldehyde enzyme Therefore, the oxidation of acetaldehyde is slow, and therefore the normal metabolism is inhibited by the toxic action of acetaldehyde and / or ethyl alcohol which is not oxidized, and various hangover phenomenon is felt. In order to alleviate the hangover after drinking alcohol, a large number of drinks prepared by mixing or combining herbal preparations or artificial preparations have been developed.
한편, 에탄올은 술의 주성분으로 신체적, 정신적으로 인체에 미치는 효과가 광범위하고 매우 다양하여 그 대사과정과 독성발현 특성에 대한 연구가 오랫동안 폭넓게 진행되어 왔다. 전술한 바와 같이, 섭취된 에탄올은 소장 및 소화관을 통해서 흡수되어 섭취 후 20 내지 120분 사이에 최고 혈중농도에 도달하게 되고 이와 같이 흡수된 에탄올은 간을 비롯한 모든 장기에서 대사되는데, 이 중 약 10% 정도는 호흡을 통하여 또는 소변 및 땀으로 배설되고 나머지 대부분은 간에서 분해된다.On the other hand, ethanol is the main ingredient of alcohol and physical and mental effects on the human body has a wide range and a variety of studies on its metabolic process and toxic expression has been extensively studied for a long time. As described above, the ethanol consumed is absorbed through the small intestine and digestive tract and reaches a maximum blood concentration within 20 to 120 minutes after ingestion. The ethanol thus absorbed is metabolized in all organs including the liver, and about 10 % Are excreted through respiration or by urine and sweat, and most of the other is cleaved in the liver.
간에서의 에탄올 분해는 산화반응을 통한 아세트알데히드로의 전환이 주된 대사가 된다. 이는 상기한 알코올 탈수소효소, 마이크로좀 에탄올 산화계(microsomal ethanol-oxidizing system, MEOS) 및 카탈라제(catalase) 등 3가지의 반응 효소계에 의해 진행되는 것으로 알려져 있다(K. Ebihara et al., Agri. Biol. Chem., 52, 1311, 1988). 이와 같은 에탄올의 분해기작 뿐 아니라 독성학적 연구도 다양하게 이루어졌는데, 에탄올의 독성은 신경학적 측면에서 관찰될 뿐만 아니라 유전학적으로도 영향을 끼친다는 보고가 있다(J. Caballeria et al., Life Sci., 41, 1021-1727, 1986). 따라서 최근 들어, 에탄올의 독성을 경감시키거나 독성의 발현을 저해할 수 있는 많은 물질에 대한 연구와 실험이 진행되고 있으며, 그 결과 천연 식품이나 한약재료로부터 추출한 성분을 함유한 다양한 건강보조식품이 이와 관련되어 개발되고 있는 실정이다(김정한 등, 한국농화학회지, 38(6), 549-553, 1995).The ethanol degradation in the liver is the main metabolism through the oxidation reaction to acetaldehyde. This is known to be carried out by three reaction enzyme systems such as alcohol dehydrogenase, microsomal ethanol-oxidizing system (MEOS), and catalase (K. Ebihara et al., Agri. Biol. Chem., 52, 1311, 1988). In addition to the decomposition mechanism of ethanol, various toxicological studies have been conducted. It is reported that ethanol toxicity is not only observed from a neurological point of view, but also genetically (J. Caballeria et al., Life Sci). , 41, 1021-1727, 1986). Therefore, in recent years, research and experiments on a number of substances that can reduce the toxicity or inhibit the expression of ethanol is in progress, and as a result, various dietary supplements containing ingredients extracted from natural or herbal ingredients It is being developed in relation to the situation (Kim Jung-han et al., Korea Journal of Agricultural Chemistry, 38 (6), 549-553, 1995).
상기 알콜성 간질환으로는 지방간, 급성간염, 만성간염, 간경변증과 간암이 있는데 이중 지방간은 가장 가벼운 증상을 보이는 동시에 가장 높은 발생빈도를 나타낸다. The above-mentioned alcoholic liver diseases include fatty liver, acute hepatitis, chronic hepatitis, liver cirrhosis and liver cancer. The fatty liver shows the lightest symptom and the highest incidence.
따라서 우리나라의 독특한 음주문화를 고려할 때 간질환 사망률을 줄이기 위해서는 초기에 알콜성 간질환을 적절히 치료해야 하지만 아직 우리나라에는 알콜성 간질환 치료제가 개발되어있지 않은 실정이다.
Therefore, considering the unique drinking culture of Korea, alcoholic liver disease should be properly treated in order to reduce the mortality rate of liver disease, but alcoholic liver disease treatment agent has not been developed in Korea yet.
칡(Pueraria thunbergian B.)은 콩과(Leguminosae)에 속하는 다년생초본의 근경으로서, 그 성분으로 이소플라본 (isoflavone) 성분인 푸에라린(puerarin), 푸에라린 자일로스(puerarin xylose), 다이드진(daidzein), 시토스테롤(sitosterol), 전분 등을 함유하는 것으로 알려져 있으며, 칡의 꽃을 갈화라 칭한다(정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 704-706, 1998). 칡 ( Pueraria thunbergian B.) is a root of perennial herb belonging to legumes (Leguminosae), and its components include isoflavone, puerarin, puerarin xylose, and diedzein. It is known to contain the sitosterol, starch, etc., and the flower of the 칡 is called a gallium (Jung Ji-seop and Shin Mingyo ) , Dohae Hyangje (Medicinal Medicine) , Yeonglimsa, pp 704-706, 1998).
뽕나무(Morus alba L.)는 뽕나무과(Moraceae)에 속하는 낙엽교목으로서, 뽕나무 잎을 상엽이라 하고, 근피의 코르크층을 제거한 근피를 상백피(상근백피), 그 가지를 상지, 그 열매를 상심(오디), 그 씨를 상심자라 각각 칭하며, 상엽 성분으로 루틴(rutin), 퀘르세린(quercetin), 노라세틴(moracetin), 유게놀(eugenol) 등의 정유성분, 팔미틴산(palmitic acid) 등의 지방산, 트리고넬린(trigonelline) 등의 성분이 알려진 바 있다(정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 545-548, 1998). Morus alba L.) is a deciduous tree belonging to the Moraceae family, and the mulberry leaves are called the upper leaves, and the root bark from which the cork layer of the root bark has been removed is the upper bark (ordinary bark), the branches are upper, the fruits are lower (audi), and the seeds are lower It is called each of the leaves, and the essential ingredient of rutin, quercetin, moracetin, eugenol and the like, fatty acids such as palmitic acid, trigonelline, etc. Ingredients are known (Information and Shin Min-kyo ) , Dohae Hyangje (Medicinal Herbs ) , Yeonglimsa, pp 545-548, 1998).
오미자(Schisandra chinenesis B.)는 목련과(Magnoliaceae)에 속하는 낙엽덩굴성 목본으로서, 오미자 및 그 동속식물의 과실을 오미자라 하고, 오미자 성분으로 데옥시쉬잔드린(deoxyschizandrin), 쉬잔드린(schizandrin), 세스퀴카렌(sesquicarene) 등의 정유 성분 등의 성분이 알려진 바 있다(정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 471-473, 1998). Schisandra chinenesis B.) is a deciduous tree belonging to the Magnoliaceae. The fruit of Schisandra chinensis and its related plants is called Schisandra chinensis and deoxyschizandrin, schizandrin, sesquikarene (Schisandrarin) sesquicarene) it is known components of the essential oil component, such as bar, such as a (jeongboseop and sinmingyo low, illustrated hyangyak (herbal) Dictionary, Younglim four, pp 471-473, 1998).
헛개나무(Hovenia dulcis T.)는 갈매나무과(Rhamnaceae)에 속하는 낙엽교목으로서, 헛개나무(Hovenia dulcis) 및 동속식물의 수피를 지구목피, 그 입을 지구엽, 그 뿌리를 지구근, 그 과실을 지구자라 각각 칭하며, 지구근 성분으로는 플란굴라닌(frangulanine), 호베닌(hovenine), 호베노시드(hovenoside) 등을 함유하고, 소화불량, 관절염 치료 등의 효능이 알려져 있다 (정보섭, 신민교, 도해향약대사전, 영림사, pp291-293, 1998). Hovenia dulcis T. is a deciduous tree belonging to the family of Rhamnaceae. The bark of the Hovenia dulcis and the same plant is the bark of the bark, the earth's mouth, the roots of the earth, the fruit of the earth. It is called each and grows, and it contains flagugulanine, hovenine, hobenoside, etc., and it is known to treat indigestion and arthritis. Hyangjedae Dictionary, Younglimsa, pp291-293, 1998).
국화(Chrysanthemum morifolium R.)는 국화과(Compositae)에 속하는 다년성초본으로서, 국화의 꽃부분을 국화라 하고 그 성분으로 크리산테민(chrysanthemin), 아미노산(amino acid), 아데닌(adenine), 루테올린-7-글루코시드(luteolin-7-glucoside),크리산테논(chrtsanthenone), 코스모시인(cosmosiin), 아카시인(acaciin) 등의 정유 성분 등의 성분이 알려진 바 있다 (정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 1039-1040, 1998). Chrysanthemum morifolium R.) is a perennial herb belonging to Compositae, and the flower part of the chrysanthemum is called chrysanthemum, and its components are chrysanthemin, amino acid, adenine, and luteolin-7-glucose. Components such as essential oils such as luteolin-7-glucoside, chrysanthenone, cosmosiin, and acaciin have been known (Information and Shinmingyo ) , Younglim, pp 1039-1040, 1998).
귤(Citrus unshiu M.)은 운향과(Rutaceae)에 속하는 상록 소교목으로서, 귤 및 동속식물의 과실을 첨등, 미성숙과실의 과피를 청피, 성숙한 과피를 귤피 또는 진피, 종자를 귤핵, 입을 귤엽이라 각각 칭하고 그 성분으로 헤스페리딘(hesperidin), 사관산, 구기산, 사세바로스(sacebarose), 크립토잔틴(cryptoxanthin), 비타민 B, C 등의 성분이 알려진 바 있다 (정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 783-785, 1998). Citrus unshiu M.) is an evergreen sub-tree belonging to the Rutaceae family, with the fruits of tangerine and the same plant being added, the skins of immature fruits called green skins, the mature skins called tangerines or dermis, the seeds tangerine cores, and the tangerine leaves. with hesperidin (hesperidin), Military acid, ball acid, sachet Barros (sacebarose), crypto-xanthine (cryptoxanthin), are known components of the vitamin B, C (jeongboseop and sinmingyo low, illustrated hyangyak (herbal) Dictionary, Younglim four , pp 783-785, 1998).
맥문동(Liriope rhizoma)은 백합과에 속하는 다년생초본인 맥문동(Liriope platyphylla) 또는 개맥문동 (Ophiopogon Japonicus)의 괴경을 건조한 것으로, sitosterol, stigmaterol, ophioside 등의 성분을 함유하고 있고, 항균 작용, 혈당강하작용 등의 약리작용이 있다고 알려져 있다.(정보섭외 향약대사전, 영림사, p177-178, 1998년).Maekmundong (Liriope rhizoma) is a perennial plant belonging to the family Liliaceae maekmundong (Liriope platyphylla) or more maekmundong (Ophiopogon Japonicus ) is a dried tuber that contains ingredients such as sitosterol, stigmaterol, ophioside, and is known to have pharmacological effects such as antimicrobial activity and hypoglycemic activity. (Information Interference Pharmacological Dictionary, Younglimsa, p177-178, 1998 year).
만삼(Conodopsis pilosula N.)는 초롱꽃과(Campanulaceae)에 속하는 다년생 초본으로서, 만삼의 뿌리를 당삼(만삼)이라 칭하고 식욕부진, 구갈, 설사 등의 치료에 사용되어 왔다 (정보섭 및 신민교 저, 도해향약(생약)대사전, 영림사, pp 1088-1089, 1998).Ten thousand and three (Conodopsis pilosula N.) has been used for the treatment of a perennial plant belonging to campanulaceae (Campanulaceae), referred to as the root of ten thousand and three dangsam (ten thousand and three), loss of appetite, dry mouth, diarrhea (jeongboseop and sinmingyo me, illustrations hyangyak ( Drug) Daesaeng, Yeonglimsa, pp 1088-1089, 1998).
그러나 상기 문헌 어디에도 갈화(칡꽃), 상심(오디), 오미자, 상엽(뽕잎), 지구자(헛개나무열매), 국화(국화), 진피(귤껍질), 맥문동 및 당삼(만삼)으로 구성된 복합생약 추출물을 유효성분으로 함유하는 간 질환 및 숙취 해소에 대한 효과에 대한 어떠한 개시 또는 교시된 바가 없다. However, even in the above literature, a compound herb consisting of brown flowers, mulberry, mulberry, lettuce leaves, mulberry leaves, chrysanthemum, chrysanthemum, dermis, tangerine, and ginseng There is no disclosure or teaching on the effect on liver disease and hangover relief containing the extract as an active ingredient.
이에 본 발명자들은 복합제제 추출물이 in vitro 상에서 ADH 및 ALDH 효소 수준을 억제하고 in vivo 상에서는 Ethanol과 Acetaldehyde의 혈중 농도를 유의적으로 억제하는 숙취해소 및 간질환에 대한 치료 효과를 확인함으로써, 본 발명을 완성하였다.
The inventors of the present invention is a combination preparation extract in inhibits ADH and ALDH enzyme levels in vitro and in In vivo , the present invention was completed by confirming a therapeutic effect on hangover and liver disease that significantly inhibit blood levels of Ethanol and Acetaldehyde.
상기 목적을 달성하기 위하여, 본 발명은 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼으로 구성된 복합생약 추출물을 유효성분으로 함유하는 숙취해소 및 간질환의 예방 및 치료용 약학조성물을 제공한다.In order to achieve the above object, the present invention is a pharmaceutical for the prevention and treatment of hangover and liver disease containing a complex herbal extract consisting of brown hair, lettuce, Schisandra chinensis, upper leaf, earth, chrysanthemum, dermis, Macmundong and Ginseng as an active ingredient To provide a composition.
구체적으로, 본원에서 정의되는 복합생약은 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼의 상대 중량 배합(w/w)비가 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10, 바람직하게는, 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5, 보다 바람직하게는, 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2의 배합비로 배합됨을 특징으로 한다.Specifically, the compound herbal as defined herein has a relative weight compound (w / w) ratio of brown, chopped, schizandra, lettuce, earth, chrysanthemum, dermis, macmundong and ginseng from 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10, preferably, 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5, more preferably 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2 : It is characterized by blending in the compounding ratio of 1-2.
본원에서 정의되는 추출물은 물, 메탄올, 에탄올, 부탄올 또는 이들의 혼합용매로부터 선택되어진 용매, 바람직하게는 물, 메탄올, 부탄올 또는 이들의 혼합용매에 가용한 추출 화합물, 보다 바람직하게는 물 및 에탄올 혼합용매, 보다 더 바람직하게는 물에 가용한 물 추출물을 포함한다.Extracts as defined herein are extract compounds available in a solvent selected from water, methanol, ethanol, butanol or a mixed solvent thereof, preferably water, methanol, butanol or a mixed solvent thereof, more preferably water and ethanol mixed Water extracts soluble in a solvent, even more preferably water.
본원에서 정의되는 간 질환은 자가면역성 간질환, 약물유인성 간질환, 알코올성 간질환, 비알콜성 간질환, 감염성 간질환, 선천성대사성 간질환, 급성간염, 만성간염, 간경변증, 간경화, 지방간 또는 간암, 바람직하게는, 알코올성 간질환 또는 비알콜성 간질환을 포함한다.
Liver diseases as defined herein include autoimmune liver disease, drug-induced liver disease, alcoholic liver disease, nonalcoholic liver disease, infectious liver disease, congenital metabolic liver disease, acute hepatitis, chronic hepatitis, liver cirrhosis, cirrhosis, fatty liver or liver cancer, Preferably, alcoholic liver disease or non-alcoholic liver disease is included.
이하, 본 발명의 추출물을 수득하는 방법을 상세히 설명한다.Hereinafter, the method for obtaining the extract of the present invention will be described in detail.
예를 들어, 추출물은 원재료인 건조 상태의 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼을 일정비, 바람직하게는, 그 상대 배합(w/w)비가 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10: 1 내지 10, 바람직하게는, 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5: 1 내지 5, 보다 바람직하게는, 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2: 1 내지 2의 배합비로 배합하는 제 1단계; 추출용매로서 물, C1 내지 C4의 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물 및 에탄올 혼합 용매를 건조된 상기 원재료 중량의 약 1 내지 5배, 바람직하게는 2 내지 4배를 가하여, 5 내지 100℃, 바람직하게는 20 내지 90℃에서, 더 바람직하게는 실온 또는 80℃에서 10시간 내지 30시간, 바람직하게는 약 18 내지 25시간 동안 냉침추출, 열수추출, 초음파 추출, 환류냉각 추출 또는 가열추출법, 바람직하게는 냉침 추출법으로 추출한 후 여과하고 감압 농축하여 본 발명의 추출물을 수득가능하다.For example, the extract is a raw material of the dried state of brown, heart, Schizandra chinensis, lettuce, earth, chrysanthemum, dermis, Macmundong and Ginseng in a certain ratio, preferably, the relative ratio (w / w) of 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10: 1 to 10, preferably, 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5: 1 to 5, more preferably 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2: 1 to 2 : 1 to 2: 1 to 2: blending in a blending ratio of 1 to 2: 1; Water, a lower alcohol of C 1 to C 4 or a mixed solvent thereof, preferably water and an ethanol mixed solvent, is added by about 1 to 5 times, preferably 2 to 4 times the weight of the dried raw material, More preferably at room temperature or at 80 占 폚 for 10 to 30 hours, preferably for about 18 to 25 hours, at a temperature of 5 to 100 占 폚, preferably 20 to 90 占 폚, Or a heat extraction method, preferably a cold extraction method, followed by filtration and concentration under reduced pressure to obtain the extract of the present invention.
또한 추가로 통상의 분획 공정을 수행할 수도 있다(Harborne J.B. Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. pp6-7, 1998).
It is also possible to further carry out conventional fractionation processes (Harborne JB Phytochemical methods: A guide to modern techniques of plant analysis, 3rd Ed. Pp 6-7, 1998).
따라서, 본 발명은 상기 제조방법 및 상기 제조방법으로 얻어진 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼으로 구성된 복합생약 추출물을 유효성분으로 함유하는 숙취해소 및 간질환의 예방 및 치료용 약학조성물을 제공한다.Accordingly, the present invention is a hangover relief and prevention of liver disease containing a complex herbal extract consisting of browning, lettuce, Schisandra chinensis, upper leaf, earth, chrysanthemum, dermis, Macmundong and Ginseng as an active ingredient obtained by the production method and the manufacturing method And it provides a pharmaceutical composition for treatment.
상기에서 제조된 조합 추출물은 in vitro 상에서 ADH 및 ALDH 효소 수준을 억제하고 in vivo 상에서는 Ethanol과 Acetaldehyde의 혈중 농도를 유의적으로 억제하는 숙취해소 및 간질환에 대한 치료 효과를 확인하였다.The combination extract prepared above is in inhibits ADH and ALDH enzyme levels in vitro and in In vivo, the effects of ethanol and Acetaldehyde on hangover and liver disease were significantly inhibited.
본 발명의 약학 조성물은 조성물 총 중량에 대하여 상기 추출물을 0.1 내지 50 중량%로 포함한다.The pharmaceutical composition of the present invention comprises 0.1 to 50% by weight of the above extract, based on the total weight of the composition.
그러나 상기와 같은 조성은 반드시 이에 한정되는 것은 아니고, 환자의 상태 및 질환의 종류 및 진행 정도에 따라 변할 수 있다.However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.
본 발명의 추출물 자체는 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있는 약제이다. Since the extract of the present invention has little toxicity and side effects, it can be safely used even for long-term administration for the purpose of prevention.
본 발명의 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명의 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The composition of the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like.
본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.5 g/kg 내지 5 g/kg으로, 바람직하게는 1 g/kg 내지 3 g/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수 있다. 따라서, 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.5 g / kg to 5 g / kg, preferably 1 g / kg to 3 g / kg per day. The administration may be carried out once a day or divided into several doses. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.
본 발명의 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다.
The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
또한, 본 발명은 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼으로 구성된 복합생약 추출물을 유효성분으로 함유하는 숙취해소 및 간질환의 예방 및 개선용 건강기능식품을 제공한다. In another aspect, the present invention provides a health functional food for the hangover and the prevention and improvement of liver disease, containing a complex herbal extract consisting of brown hair, lettuce, Schisandra chinensis, upper leaf, earth, chrysanthemum, dermis, Macmundong and Ginseng as an active ingredient. .
본원에서 정의되는 "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.&Quot; Health functional food "as defined herein means food prepared and processed using raw materials or ingredients having functionality useful to the human body in accordance with Law No. 6727 on Health Functional Foods." Functional " Structure and function of the nutrient to control or physiological effects, such as to obtain a beneficial effect for health is intended to eat.
본 발명의 숙취해소 및 간질환 예방을 위한 건강기능식품은, 조성물 총 중량에 대하여 상기 추출물을 0.01 내지 95 %, 바람직하게는 1 내지 80 % 중량백분율로 포함한다.Health functional food for the hangover and liver disease prevention of the present invention, the extract comprises 0.01 to 95% by weight, preferably 1 to 80% by weight relative to the total weight of the composition.
또한, 숙취해소 및 간질환 예방을 위한 목적으로 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태인 건강기능식품으로 제조 및 가공이 가능하다.In addition, it is possible to manufacture and process as a health functional food in the form of tablets, capsules, powders, granules, liquids, pills for the purpose of relieving hangovers and preventing liver diseases.
본 발명은 숙취해소 및 간질환의 예방 및 개선의 효과를 나타내는 상기 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼으로 구성된 복합생약 추출물을 포함하는 건강보조식품을 제공한다. 상기 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.The present invention provides a dietary supplement comprising a complex herbal extract consisting of the browning, lettuce, Schisandra chinensis, lettuce, earth, chrysanthemum, dermis, myeongmundong and ginseng showing the effect of relieving hangover and preventing and improving liver disease. Examples of foods to which the extract can be added include various foods, beverages, gums, tea, vitamin complexes, and health functional foods.
본 발명의 추출물을 포함하는 조성물은 숙취해소 및 간질환의 예방 및 개선을 위한 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The composition comprising the extract of the present invention can be used in various ways, such as drugs, foods and beverages for hangover relief and prevention and improvement of liver disease. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used as powders, granules, tablets, capsules or beverages have.
또한, 본 발명은 숙취해소 및 간질환의 예방 및 개선효과를 갖는 갈화, 상심, 오미자, 상엽, 지구자, 국화, 진피, 맥문동 및 당삼으로 구성된 복합생약 추출물을 주성분으로 함유하는 식품 또는 식품첨가제를 제공한다. 본 발명의 추출물은 숙취해소 및 간질환의 예방 및 개선을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 일반적으로 본 발명의 건강식품 조성물은 전체 식품 중량의 1 내지 5 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. In addition, the present invention is a food or food additive containing a complex herbal extract consisting of browning, lettuce, Schisandra chinensis, lettuce, earth, chrysanthemum, dermis, Macmundong, and Ginseng as a main component to relieve hangover and prevent and improve liver disease to provide. Extract of the present invention can be added to food or beverages for the purpose of relieving hangovers and preventing and improving liver disease. At this time, the amount of the extract in the food or beverage is generally the health food composition of the present invention can be added to 1 to 5% by weight of the total food weight, the health beverage composition is 0.02 to 10 g, preferably based on 100 ml Can be added in a ratio of 0.3 to 1 g.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등)) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.
The health beverage composition of the present invention may contain various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient, as long as it contains the extract as an essential ingredient at the indicated ratio, and there is no particular limitation to the liquid ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. have. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 mL of the composition of the present invention.
본 발명의 숙취해소용 조성물을 함유하는 것이 바람직하다.It is preferable to contain the composition for hangover decay of the present invention.
또한, 본 발명은 본 발명에 따른 숙취해소용 조성물을 포함하는 숙취해소용 껌을 제공한다. 예를 들어, 상기 숙취해소용 껌은 본 발명에 따른 숙취해소용 조성물에 껌의 제조에 필요한 일반적인 성분들, 예컨대 껌베이스와 설탕, 포도당, 이소말트 또는 자일리톨과 같은 당류 등을 첨가하여 당업계에 공지된 통상의 방법에 따라 제조될 수 있다. 이외 껌의 물성을 부드럽게 하고, 껌이 잘 뭉쳐지게 하기 위하여 당류 시럽, 예컨대 솔티톨 80, 물엿, 말티톨 시럽 또는 솔비톨 시럽 등이 첨가되어 제조될 수 있다. 또한, 향료, 안정제, 색소, 유화제 및 광택제로 이루어진 군에서 선택되는 하나 이상이 추가로 첨가되어 제조될 수 있다. 상기 향료는 껌의 향을 우수하게 하기 위하여 첨가되는 것으로서, 민트향, 과일향 또는 허브향의 향료를 사용할 수 있다. 또한, 상기 안정제로는 검 아라빅(gum arabic), 젤라틴(gelatin) 또는 카라기난(carageenan) 등을 사용할 수 있다. 이와 같은 안정제의 첨가로 인해 가공시 가열이나 보존 중의 변화에 대해 신선도를 유지하고 형태를 보존할 수 있으며, 껌의 식감이나 촉감을 높일 수 있다. 또한, 본 발명에 따른 숙취해소용 껌은 시각적 효과를 높이기 위하여 치자청색소, 치자황색소, 카라멜 색소 또는 포도과피추출색소와 같은 천연색소 또는 합성 착색료가 추가로 첨가되어 제조될 수 있다. 나아가, 향료를 당액에 골고루 분산시키기 위하여 자당지방산에스테르 또는 레시틴(lecithin)과 같은 유화제와 껌의 시각적 효과를 높이기 위하여 카나우바 왁스(carnauba wax) 또는 쉘락(shellac)과 같은 광택제가 추가로 첨가되어 제조될 수 있다. 본 발명에 따른 숙취해소용 껌은 1.6g의 껌 1개 당 본 발명에 따른 숙취해소용 조성물 50-500mg, 보다 바람직하게는 150mg을 포함하는 것이 바람직하다.In addition, the present invention provides a hangover chew gum comprising the composition for hangover resolution according to the present invention. For example, the hangover gum may be prepared by adding to the composition for minor hangover according to the present invention the general components necessary for the production of gum, such as gum base and saccharides such as sugar, glucose, isomalt or xylitol, Can be prepared according to the usual known methods. In order to smooth the physical properties of the gum and to make the gum cohesive, saccharide syrups such as, for example, Soltitol 80, starch syrup, maltitol syrup or sorbitol syrup may be added. In addition, at least one selected from the group consisting of fragrances, stabilizers, pigments, emulsifiers and brighteners can be further added. The fragrance is added to excellence of the gum flavor, and a fragrance such as a mint flavor, a fruit flavor or a herb flavor can be used. The stabilizer may be gum arabic, gelatin, carageenan, or the like. With the addition of such stabilizers, the freshness can be maintained, the shape can be preserved, and the texture and texture of the gum can be enhanced against changes during heating or preservation during processing. In addition, the hangover chewing gum according to the present invention may be prepared by further adding natural coloring matters or synthetic coloring matters such as a flower gum, a gardenia yellow color, a caramel color or a grape skin extract pigment to enhance visual effects. Furthermore, emulsifying agents such as sucrose fatty acid esters or lecithin and polishes such as carnauba wax or shellac are further added to enhance the visual effect of the gum to uniformly disperse the flavor in the sugar solution, . The chewable gum according to the present invention preferably contains 50-500 mg, more preferably 150 mg, of the composition for a hangover remedy according to the present invention per 1.6 g of gum.
본 발명에 따른 숙취해소용 조성물은 상기 음료와 껌 이외에 복용하기 편리한 현탁제, 환제, 정제, 캅셀제, 산제 등으로 다양하게 제형화되어 사용될 수 있다. 이러한 제형은 당업계에 공지된 통상적인 방법을 이용하여 제조될 수 있다The composition for hangover decay according to the present invention may be formulated into various forms such as suspensions, pills, tablets, capsules, powders and the like, which are convenient to take in addition to the beverage and gum. Such formulations may be prepared using conventional methods known in the art
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 추출물은 in vitro 상에서 ADH 및 ALDH 효소 수준을 억제하고 in vivo 상에서는 Ethanol과 Acetaldehyde의 혈중 농도를 유의적으로 억제하는 숙취해소 및 간질환에 대한 치료 효과를 확인하여, 숙취해소 및 간질환의 예방 및 치료용 조성물에 유용하게 이용될 수 있다.
Extract of the present invention in In vitro, ADH and ALDH enzyme levels are inhibited, and in vivo, ethanol and Acetaldehyde significantly inhibit blood levels of hangover and liver disease. It can be usefully used.
도 1은 복합제제 추출물의 알콜 분해능에 대한 효과를 나타낸 도이고,
도 2는 복합제제 추출물의 아세트알데히드 수준에 대한 억제활성을 나타낸 도이며,
도 3은 복합제제 추출물의 혈중 ADH (알코올탈수소효소) 및 ALDH에 대한 활성을 나타낸 도이다.1 is a view showing the effect on the alcohol resolution of the combination preparation extract,
Figure 2 is a diagram showing the inhibitory activity against acetaldehyde level of the combination preparation extract,
Figure 3 is a diagram showing the activity of ADH (alcohol dehydrogenase) and ALDH in the blood of the combination preparation extract.
이하, 본 발명을 실시예 및 실험예에 의해 상세히 설명한다. Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
실시예Example 1. 복합제제 추출물의 제조 1. Preparation of complex preparation extract
경일유통약업사에서 구입한 갈화(18,000 g), 상심(18,000 g), 오미자(18,000 g), 상엽(18,000 g), 지구자(18,000 g), 국화(18,000 g), 진피(18,000 g), 맥문동(18,000 g) 및 당삼(18,000 g)에 물 1,500ℓ를 투입하고, 100℃에서 6시간 추출하여, 추출액(이하 KRW이라 함)을 수득하였다.
Gallium (18,000 g), Sangsim (18,000 g), Schisandra chinensis (18,000 g), Lettuce (18,000 g), Seongja (18,000 g), Chrysanthemum (18,000 g), Dermis (18,000 g), Macmundong (18,000 g) and 1,500 L of water were added to Ginseng (18,000 g), followed by extraction at 100 ° C. for 6 hours to obtain an extract (hereinafter referred to as KRW).
참조예 1. 실험준비 Reference Example 1. Preparation for experiment
1-1. 시료준비1-1. Sample Preparation
실험에 사용하기 위한 시료로서 복합제제 추출물을 사용하였다.
The combination formulation extract was used as a sample for use in the experiment.
1-2. 실험 동물1-2. Experimental animal
실험에 사용하기 위한 실험동물은 무게 200-250 g의 자성 Sprague Dawley rat을 사용하였으며, 고형 시료와 수돗물을 자유 섭취케 하여 48시간 안정화하고 2주간 예비사육 후 시험에 사용하였다.
The experimental animals used for the experiment were magnetic Sprague Dawley rats weighing 200-250 g. The samples were stabilized for 48 hours by free intake of solid samples and tap water, and used for the test after two weeks of pre-breeding.
1-3. 1-3. 실험군Experimental group
하기와 같이 실험 군을 구분하여 실험을 수행하였다.(표 1참조)
Experiments were performed by dividing the experimental groups as follows. (See Table 1)
1-4. 통계처리1-4. Statistical processing
모든 실험 결과는 ANOVA (one way analysis of variance)를 이용하여 통계 처리하였고, 유의성이 인정될 경우 스튜던트-뉴만-케울스 검정법(Student-Newman-Keuls Test)를 사용하여 p < 0.05 수준 이하에서 유의성 검정을 실시하였다.
All experimental results were statistically analyzed using one way analysis of variance (ANOVA), and significance was tested at p <0.05 level using the Student-Newman-Keuls Test if significant. Was carried out.
실험예 1. 알콜분해능 측정Experimental Example 1. Determination of alcohol resolution
상기 실시예에서 얻은 시료의 래트에서의 알콜 분해 활성을 알아보기 위해 기존 문헌에 기재된 방법을 이용하여 하기와 같이 실험을 수행하였다((재)한국보건공정서연구회 회장, 건강기능식품의 기능성시험가이드, (재)한국보건공정서연구회, pp 303-344, 2004).
In order to determine the alcohol degradation activity in the rat of the sample obtained in the above example, the experiment was performed using the method described in the existing literature as follows (Research Chairman, Korea Institute of Health and Procedure , Functional Test Guide of Health Functional Food) , Korea Institute of Health Process, pp 303-344, 2004).
1-1. 혈중 1-1. Blood 알콜Alcohol 농도측정 Concentration measurement
상기 실시예 1에서 얻어진 추출물의 숙취해소 효과를 측정하기 위하여, 알콜을 섭취한 실험동물에 상기 추출물을 투여하여 혈중 알콜농도를 측정하였다. 구체적으로, 실험동물은 무게 200-250 g의 자성 Sprague Dawley rat을 사용하였으며, 고형 시료와 수돗물을 자유 섭취케 하여 2주간 예비사육 후 시험에 사용하였다. 18시간 절식 후, 실험군에는 시험시료를 10 ㎖/Kg 농도로 경구 투여하였고 대조군은 물만 10 ㎖/kg을 투여하였다. 경구투여는 스테인레스 스틸 존데(길이, 10cm)를 사용하여 강제 경구 투여하였다. 실험시료 투여 30분 후에 40% 에탄올 2ml을 스테인레스 스틸 존데(길이, 10cm)를 사용하여 강제 경구 투여하였다. 실험시료 투여 후 1시간, 3시간, 5시간 3회 채혈하고, 1시간, 3시간은 꼬리를 절단하여 채혈하였으며, 5시간은 복부대동맥에서 실린지를 이용하여 채혈하였고 채혈한 혈액은 3000rpm에서 20분간 원심분리 하여 혈청을 분리하였다. 분리한 혈청을 Ethanol Kit(Sigma, U.S.A)을 이용하여 파장 340nm에서 측정하였다.
In order to measure the hangover relief effect of the extract obtained in Example 1, the extract was administered to the experimental animal ingested alcohol to measure the blood alcohol concentration. Specifically, the experimental animals used a magnetic Sprague Dawley rat weighing 200-250 g, and used for the test after preliminary breeding for two weeks by allowing free intake of solid samples and tap water. After 18 hours of fasting, the test group was orally administered with a test sample at a concentration of 10 ml / Kg, and the control group was administered only 10 ml / kg of water. Oral administration was forced oral administration using stainless steel sonde (length, 10 cm). Thirty minutes after the test sample administration, 2 ml of 40% ethanol was forced orally administered using stainless steel sonde (length, 10 cm). 1 hour, 3 hours, 5 hours, 3 times, 1 hour, 3 hours after cutting the tail, blood was cut by cutting the tail, 5 hours were collected using a syringe in the abdominal aorta and the blood collected was 20 minutes at 3000rpm Serum was separated by centrifugation. The separated serum was measured at wavelength 340nm using Ethanol Kit (Sigma, USA).
1-2. 혈중 아세트알데히드 농도측정1-2. Blood Acetaldehyde Level Measurement
아세트알데히드탈수소효소의 활성 측정은 흡광도 340 nm에서 NADH의 생성 속도를 지표로 사용하였다. 반응액의 조성은 증류수 2 ㎖, 1 M tris-HCl(pH 8.0) 0.3 ㎖, 20 mM NAD+0.1 ㎖, 1 M 아세트알데히드 0.1 ㎖, 시료 0.1㎖의 혼합액과 효소원 0.1 ㎖을 큐벳(cuvette)에 넣어 총 3 ㎖이 되도록 조절하여 30℃에서 5분간 전 반응시킨 후, 5분간 340 nm에서 흡광도의 변화를 측정하였다. 이때, 시료를 첨가하지 않은 것을 대조군으로 하여 시료의 아세트알데히드탈수소효소 활성은 대조군에 대한 상대활성(%)으로 측정하였다.
Acetaldehyde dehydrogenase activity was measured by the rate of NADH production at an absorbance of 340 nm. The composition of the reaction solution was cuvetted with 2 ml of distilled water, 0.3 ml of 1 M tris-HCl (pH 8.0), 20 mM NAD + 0.1 ml, 0.1 ml of 1 M acetaldehyde, 0.1 ml of sample and 0.1 ml of enzyme source. The reaction was adjusted to a total of 3 ml and reacted for 5 minutes at 30 ° C., and then the change in absorbance at 340 nm was measured for 5 minutes. At this time, the acetaldehyde dehydrogenase activity of the sample was measured as the relative activity (%) relative to the control group was added as a control.
본 실험 결과, 도 1 및 도 2에 나타난 바와 같이, 본 발명의 복합제제가 시중 유명 숙취 해소 제품보다 숙취해소효과가 탁월하고 보다 탁월한 알콜 분해능 및 아세트알데히드 감소 활성을 나타내 본 발명의 조성물이 숙취해소에 유용함을 확인할 수 있었다.
As a result of the experiment, as shown in Figures 1 and 2, the composite formulation of the present invention is superior to the hangover remedy products on the market and exhibits excellent alcohol resolution and acetaldehyde-reducing activity, the composition of the present invention to hangover It could be useful.
실험예Experimental Example 2. 혈중 2. Serum ADHADH ( ( 알코올탈수소효소Alcohol dehydrogenase ) 및 ) And ALDHALDH 활성 측정( Active measurement ( inin vitrovitro ))
상기 실시예에서 얻은 시료의 혈중 ADH (alcohol dehydrogenase) 및 ALDH (acetaldehyde dehydrogenase)에 대한 억제 효과를 알아보기 위해 기존 문헌에 기재된 방법을 이용하여 하기와 같이 실험을 수행하였다((재)한국보건공정서연구회 회장, 건강기능식품의 기능성시험가이드, (재)한국보건공정서연구회, pp 303-344, 2004).
In order to determine the inhibitory effect on the blood ADH (alcohol dehydrogenase) and ALDH (acetaldehyde dehydrogenase) of the sample obtained in the above example, the experiment was carried out as follows using the method described in the existing literature (Re) Chairman of the Society, Functional Test Guide for Health Functional Foods , Korea Institute of Health Procedures, pp 303-344, 2004).
2-1. 혈중 2-1. Blood ADHADH (( 알코올탈수소효소Alcohol dehydrogenase ) 활성 측정) Active measurement
효소원은 동결건조된 S9 쥐의 간 분쇄액(rat liver homogenate)(MOLTOX Co., USA) 26.4 ㎎(최종 농도가 3.3 ㎎/㎖이 되도록 함)을 0.1% BSA(bovine serum albumin) 용액 8 ㎖에 용해하여, 0.45 μm 시린지 필터(syringe filter)로 여과하여 사용하였다. 알코올탈수소효소 활성 측정은 흡광도 340 nm에서 NADH의 생성속도를 지표로 사용하였다. 반응액의 조성은 증류수 1 ㎖, 1 M tris-HCl(pH 8.8) 0.75 ㎖, 20 nM NAD+0.3 ㎖, 에탄올 0.3㎖, 시료 0.1 ㎖의 혼합액과 효소원 0.15 ㎖를 큐벳(cuvette)에 넣어 총 3 ㎖이 되도록 조절하여 30℃에서 5분간 전반응시킨 후, 5분간 340 nm에서 흡광도의 변화를 측정하였다. 이때 시료를 첨가하지 않는 것을 대조군으로 하였다. 시료의 알코올탈수소효소 활성은 대조군에 대한 상대활성(%)으로 측정하였다.
The enzyme source was 26.4 mg of rat liver homogenate (MOLTOX Co., USA) of lyophilized S9 rats (final concentration was 3.3 mg / ml) and 8 ml of 0.1% BSA (bovine serum albumin) solution. Dissolved in and filtered through a 0.45 μm syringe filter. Alcohol dehydrogenase activity was measured using the rate of NADH production as absorbance at 340 nm. The reaction mixture consisted of 1 ml of distilled water, 0.75 ml of 1 M tris-HCl (pH 8.8), 20 nM NAD + 0.3 ml, 0.3 ml of ethanol, 0.1 ml of sample and 0.15 ml of enzyme source in a cuvette. After adjusting to 3 ml and prereacting at 30 ° C. for 5 minutes, the change in absorbance was measured at 340 nm for 5 minutes. At this time, the sample was not added as a control. Alcohol dehydrogenase activity of the sample was measured as relative activity (%) relative to the control.
2-2. 2-2. ALDHALDH ( ( acetaldehydeacetaldehyde dehydrogenasedehydrogenase )에 대한 억제활성 Inhibitory activity against
효소원은 동결건조된 S9 쥐의 간 분쇄액(rat liver homogenate)(MOLTOX Co., USA) 26.4 ㎎(최종 농도가 3.3 ㎎/㎖이 되도록 함)을 0.1% BSA(bovine serum albumin) 용액 8 ㎖에 용해하여, 0.45 μm 시린지 필터(syringe filter)로 여과하여 사용하였다. 흡광도 340 nm에서 NADH의 생성속도를 지표로 사용하였다. 반응액의 조성은 증류수 2.1 ㎖, 1.0 M tris-HCl buffer (PH 8.0) 0.3 ㎖, 20 mM NAD+ 0.1 ㎖, 1.0 M acetaldehyde 0.1 ㎖, 3.0 M KCl 0.1 ㎖, 0.33 M 2-mercaptoethanol 0.1㎖, 시료 0.1 ㎖, 효소원 0.1 ㎖를 큐벳(cuvette)에 넣어 총 3 ㎖이 되도록 조절하여 30℃에서 5분간 전반응시킨 후, 5분간 340 nm에서 흡광도의 변화를 측정하였다. 이때 시료를 첨가하지 않는 것을 대조군으로 하였다. 시료의 ALDH 활성은 대조군 상대 활성(%)으로서 측정하였다.
The enzyme source was 26.4 mg of rat liver homogenate (MOLTOX Co., USA) of lyophilized S9 rats (final concentration was 3.3 mg / ml) and 8 ml of 0.1% BSA (bovine serum albumin) solution. Dissolved in and filtered through a 0.45 μm syringe filter. The absorption rate of NADH at 340 nm was used as an index. The composition of the reaction solution was 2.1 ml of distilled water, 0.3 ml of 1.0 M tris-HCl buffer (PH 8.0), 20 mM NAD + 0.1 ml, 0.1 ml of 1.0 M acetaldehyde, 0.1 ml of 3.0 M KCl, 0.1 ml of 0.33 M 2-mercaptoethanol, and a sample. 0.1 ml and 0.1 ml of enzyme source were put in a cuvette, adjusted to a total of 3 ml, pre-reacted at 30 ° C. for 5 minutes, and then the change in absorbance at 340 nm was measured for 5 minutes. At this time, the sample was not added as a control. The ALDH activity of the sample was measured as the control relative activity (%).
상기 도 3에서 알 수 있는 바와 같이, 본 발명의 복합제제가 시중 유명 숙취 해소 제품보다 우수한 혈중 ADH (alcohol dehydrogenase) 및 ALDH (acetaldehyde dehydrogenase)에 대한 탁월한 억제 활성을 나타내 본 발명의 조성물이 알코올 대사를 촉진시킴을 알 수 있다.
As can be seen in Figure 3, the combination of the present invention exhibits superior inhibitory activity against blood ADH (alcohol dehydrogenase) and ALDH (acetaldehyde dehydrogenase) in the blood than the famous hangover treatment products on the market, the composition of the present invention promotes alcohol metabolism It can be seen.
하기에 본 발명의 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.
Hereinafter, formulation examples of the composition containing the extract of the present invention will be described, but the present invention is not intended to be limited thereto but will be specifically described.
제제예 1. 산제의 제조Preparation Example 1. Preparation of powder
KRW 추출물 20 mgKRW Extract 20 mg
유당 100 mgLactose 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
KRW 추출물 10 mgKRW Extract 10 mg
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
KRW 추출물 10 mgKRW Extract 10 mg
결정성 셀룰로오스 3 mgCrystalline cellulose 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
KRW 추출물 10 mgKRW Extract 10 mg
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4 ,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2㎖) 상기의 성분 함량으로 제조한다.
(2 ml) per 1 ampoule according to the usual injection preparation method.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
KRW 추출물 20 mgKRW Extract 20 mg
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120052744A KR101383146B1 (en) | 2012-05-18 | 2012-05-18 | Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120052744A KR101383146B1 (en) | 2012-05-18 | 2012-05-18 | Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130128755A KR20130128755A (en) | 2013-11-27 |
KR101383146B1 true KR101383146B1 (en) | 2014-04-09 |
Family
ID=49855762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120052744A KR101383146B1 (en) | 2012-05-18 | 2012-05-18 | Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101383146B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160142713A (en) | 2015-06-03 | 2016-12-13 | 대구한의대학교산학협력단 | Composition Comprising Artemisiae apiaceae Herba extracts for preventing or treating nonalcoholic fatty liver disease |
KR20170000151A (en) | 2015-06-23 | 2017-01-02 | 대구한의대학교산학협력단 | Composition comprising Spirodela polyrhiza extracts for preventing or treating nonalcoholic fatty liver disease |
KR20180040813A (en) * | 2016-10-13 | 2018-04-23 | 주식회사 비케이바이오 | Composition for dissolving hangover comprising citrus peel fermentation extract |
KR20180083146A (en) | 2017-01-12 | 2018-07-20 | 대구한의대학교산학협력단 | Composition for preventing or treating liver disease comprising pericarpium zanthoxyli extracts |
KR20210007156A (en) | 2019-07-10 | 2021-01-20 | 대구한의대학교산학협력단 | Composition comprising icaritin and quercetin for preventing or treating nonalcoholic fatty liver disease |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104322834A (en) * | 2014-10-22 | 2015-02-04 | 刘四 | Sober-up tea |
CN104606277B (en) * | 2014-12-29 | 2021-03-12 | 株式会社东洋新药 | Application of flos Puerariae Lobatae treated product, and food, beverage and cosmetic containing the same |
CN104689218A (en) * | 2015-03-31 | 2015-06-10 | 周冠旻 | Traditional Chinese medicine composition for treating fatty liver |
CN104800353A (en) * | 2015-05-02 | 2015-07-29 | 臧孝国 | Traditional Chinese medicine composition for treating hepatitis B |
KR102001026B1 (en) * | 2017-10-27 | 2019-07-17 | 경희대학교 산학협력단 | A composition for hepatoprotective or relieving hangover comprising herbal extracts complex and l- aspartic acid |
KR102001769B1 (en) * | 2018-02-06 | 2019-07-18 | 가천대학교 산학협력단 | A Composition comprising extracts, fractions or isolated compounds of Liriope platyphylla for inhibition of Hepatitis E virus proliferation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100751047B1 (en) | 2006-09-18 | 2007-08-22 | 이승도 | Food compound for obviating and curing hangover |
KR101133985B1 (en) | 2009-12-15 | 2012-04-05 | 이정호 | Beverage Using Leaf, Stem, Root Bark and Fruit of Mulberry Tree |
-
2012
- 2012-05-18 KR KR1020120052744A patent/KR101383146B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100751047B1 (en) | 2006-09-18 | 2007-08-22 | 이승도 | Food compound for obviating and curing hangover |
KR101133985B1 (en) | 2009-12-15 | 2012-04-05 | 이정호 | Beverage Using Leaf, Stem, Root Bark and Fruit of Mulberry Tree |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160142713A (en) | 2015-06-03 | 2016-12-13 | 대구한의대학교산학협력단 | Composition Comprising Artemisiae apiaceae Herba extracts for preventing or treating nonalcoholic fatty liver disease |
KR20170000151A (en) | 2015-06-23 | 2017-01-02 | 대구한의대학교산학협력단 | Composition comprising Spirodela polyrhiza extracts for preventing or treating nonalcoholic fatty liver disease |
KR20180040813A (en) * | 2016-10-13 | 2018-04-23 | 주식회사 비케이바이오 | Composition for dissolving hangover comprising citrus peel fermentation extract |
KR102685420B1 (en) | 2016-10-13 | 2024-07-17 | 주식회사 비케이바이오 | Composition for dissolving hangover comprising citrus peel fermentation extract |
KR20180083146A (en) | 2017-01-12 | 2018-07-20 | 대구한의대학교산학협력단 | Composition for preventing or treating liver disease comprising pericarpium zanthoxyli extracts |
KR20210007156A (en) | 2019-07-10 | 2021-01-20 | 대구한의대학교산학협력단 | Composition comprising icaritin and quercetin for preventing or treating nonalcoholic fatty liver disease |
KR20210084377A (en) | 2019-07-10 | 2021-07-07 | 대구한의대학교산학협력단 | Composition comprising icaritin and quercetin for preventing or treating nonalcoholic fatty liver disease |
Also Published As
Publication number | Publication date |
---|---|
KR20130128755A (en) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101383146B1 (en) | Composition comprising an extract of combined crude drug for preventing and treating hangover or liver disease | |
KR100864455B1 (en) | A Composition comprising the extract of complex herb improving Liver Cirrhosis, cytotoxicity and liver injury for preventing and treating of liver disease | |
US20110027305A1 (en) | Composition Comprising an Extract of Herbal Combination Thereof for Preventing and Treating Diabetes Mellitus | |
KR100968109B1 (en) | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof | |
KR101144059B1 (en) | Composition for prevention or treatment of diabete or obesity comprising Punica granatum extract and red ginseng extract | |
KR101406138B1 (en) | Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille | |
KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
KR100829691B1 (en) | Composition for promoting degradation of lipid containing plant extracts | |
KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
KR20080018676A (en) | Anti-diabetic food composition comprising extracts from natural herbal materials and propolis and process for preparing the same | |
KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
KR20140137288A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
KR100881369B1 (en) | A composition comprising isoliquiritigenin isolated from glycyrrhiza radix for treating and preventing drug intoxication or withdrawal | |
WO2008072799A9 (en) | Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizon for treating or preventing diabetes mellitus and the use thereof | |
KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
KR101423875B1 (en) | A composition comprising the complex extract for preventing or treating stroke and degenerative brain disease | |
KR101992174B1 (en) | Tablet-type composition for preventing and relieving hangover, and protecting hepatic caused by alcohol containing medical herbs | |
KR20200126839A (en) | Composition for relieving or improving hangover | |
KR100551464B1 (en) | Composition comprising an extract of Saururus chinensis BAILL. for preventing and treating diabetes mellitus | |
KR20140142516A (en) | A composition comprising the extract of Bupleurum falcatum (BF) and Physalis alkekengi var. francheti (PAF) as an active ingredient for preventing and treating inflammatory disease | |
KR102651713B1 (en) | Chocolate composition for relieving hangovers comprising Hovenia Dulcis fruit and Velvet Antlers, and the manufacturing method of chocolate for relieving hangovers using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |